Merial Limited

Merial Limited is an animal healthcare company focusing on pharmaceutical products and vaccines for livestock, pets, and wildlife. The company offers a wide range of products in various medicinal fields such as anaesthetic, antiparasitic, antimicrobial, gastrointestinal, respiratory, and cardiovascular medicines. Furthermore, Merial provides vaccines for addressing diseases in birds including Newcastle Disease, Marek's Disease, and Avian Flu. Some of its key products include IVOMEC for treating parasites in cattle, sheep, and swine, and FRONTLINE for treating dogs and cats. The company caters to veterinarians, pet owners, farmers, and food animal producers globally.

Established in 1997 as a 50-50 joint venture between the animal health assets of Rhône-Poulenc and Merck & Co, Merial Limited is headquartered in Duluth, Georgia and operates in numerous countries worldwide, including Argentina, the Netherlands, Australia, New Zealand, Brazil, the Philippines, Chile, Russia, China, Singapore, France, Spain, Germany, Taiwan, Italy, Thailand, Japan, the United Kingdom, Korea, the United States, Latin America, Uruguay, Mexico, and other regions globally.

Merial Limited functions as a subsidiary of Sanofi-Aventis, which acquired Rhône-Poulenc and took over Merck's 50% stake on September 17, 2009.

With its strong presence and diverse product portfolio in the biotechnology and healthcare industries, Merial Limited presents a compelling investment opportunity for venture capitalists seeking to support advancements in animal health on a global scale.